A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3

Active, not recruiting

• Conditions: Neoplasms
• Interventions: Drug: Encorafenib; Drug: Cetuximab; Drug: Irinotecan; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-FU; Drug: Capecitabine; Drug: Bevacizumab

• Registration Number: NCT04607421
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that:

* has spread to other parts of the body (metastatic);

* has a certain type of abnormal gene called "BRAF"; and

* has not received prior treatment.
...

Detailed Description

The purpose of the study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of-care chemotherapy in participants with previously untreated BRAF V600E-mutant mCRC. Since encorafenib has not previously been combined with chemotherapy, the tolerability and...

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2020-10-05
• Study First Submitted QC: 2020-10-22
• Study First Posted: 2020-10-29
• Study Start: 2020-12-21
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-12
• Last Update Posted: 2024-12-17
• Primary Completion: 2025-01-06
• Study Completion: 2026-12-24

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 816

Inclusion Criteria

• Safety Lead-In = Male/female ≥ 18 years old
• Phase 3 and Cohort 3: Male/female ≥ 16 years old (where permitted locally)
• Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation
• Prior systemic treatment in metastatic setting: 0-1 regimens for Safety Lead In; none for Phase 3 and Cohort 3. (Note: Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment )
• Measurable disease (Phase 3 and Cohort 3)/ Measurable or evaluable disease (Safety Lead-in)
• ECOG PS 0-1
• Adequate organ function

Read More

Exclusion Criteria

• Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition
• Active bacterial or viral infections in 2 weeks prior to starting dosing
• Symptomatic brain metastases

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Safety Lead-in Cohort 1	Encorafenib	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 1	Cetuximab	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 1	Irinotecan	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 1	Leucovorin	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm A	Encorafenib	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks
Phase 3 Arm A	Cetuximab	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks
Safety Lead-in Cohort 2	Leucovorin	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 2	5-FU	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm B	Oxaliplatin	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm B	Leucovorin	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm B	5-FU	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm C	Capecitabine	Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
Cohort 3 Arm D	Encorafenib	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Cohort 3 Arm E	Irinotecan	Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)
Phase 3 Arm C	Bevacizumab	Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
Cohort 3 Arm E	5-FU	Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)
Safety Lead-in Cohort 1	5-FU	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 2	Encorafenib	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 2	Cetuximab	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Safety Lead-in Cohort 2	Oxaliplatin	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm B	Encorafenib	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm B	Cetuximab	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Phase 3 Arm C	Oxaliplatin	Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
Phase 3 Arm C	Irinotecan	Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
Phase 3 Arm C	Leucovorin	Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
Phase 3 Arm C	5-FU	Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
Cohort 3 Arm D	Cetuximab	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Cohort 3 Arm D	Irinotecan	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Cohort 3 Arm D	Leucovorin	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Cohort 3 Arm D	5-FU	Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
Cohort 3 Arm E	Leucovorin	Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)
Cohort 3 Arm E	Bevacizumab	Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)

Primary Outcome Measures

Name	Time	Method
Phase 3: Progression free survival, by blinded independent review	Duration of Phase 3, approximately 36 months	Progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib and cetuximab + mFOLFOX6 (Arm B) vs the Control Arm (Arm C)
Cohort 3: Objective response rate by blinded independent review	Duration of Cohort 3, approximately 15 months.	Defined as CR, or PR according to RECIST v1.1 based on BICR assessment, from the date of randomization until the date of the first documentation of PD, death or start of new anticancer therapy
Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs)	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	Incidence of dose limiting toxicity defined as any adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment
Phase 3: Objective response rate by blinded independent review	Duration of Phase 3, approximately 23 months	Objective response defined as complete response (CR), or partial response (PR) according to RECIST v1.1 based on BICR assessment, from the date of randomization until the date of the first documentation of progression of disease (PD)

Secondary Outcome Measures

Name	Time	Method
Safety Lead-in: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion.
Cohort 3: Overall survival	Duration of Cohort 3, approximately 36 months	Overall survival, defined as the time from the date of randomization to death due to any cause
Phase 3: Progression free survival 2 by Investigator	Duration of Phase 3, approximately 36 months	Progression free survival 2, defined as the time from the date of randomization to the second objective disease progression per RECIST v1.1, or death from any cause, whichever occurs first: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encoraf...
Phase 3: Incidence of adverse events	Duration of Phase 3, approximately 36 months	An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)
Phase 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms	Duration of Phase 3, approximately 36 months	Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)
Phase 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire	Duration of Phase 3, approximately 36 months	The EQ-5D-5L is a standardized measure of health utility that provides a single index value for the participant's health status. It is frequently used for economic evaluations of health care and has been shown to be a valid and reliable instrument, and comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitivel...
Phase 3: To determine the correlation between ctDNA levels, BRAF V600 alterations, and clinical outcome	Predose on Cycle 1 Day 1, 15, Cycle 2 Day 15, Cycle 7 Day 1 and EOT. Arm C sampling on Day 1 of Cycles 1-3, 9 and EOT. EOT is approx 36 months.	ctDNA levels and BRAF V600 VAF from ctDNA analysis of plasma samples collected at baseline and on treatment
Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746 and oxaliplatin	Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days
Safety Lead-in: Clearance of irinotecan, SN-38 and oxaliplatin	Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days	Changes in exposures of irinotecan and its metabolite (SN-38) on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 1 (encorafenib and cetuximab + FOLFIRI) Changes in exposures of oxaliplatin on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 2 (encorafenib and cetuximab + mFOLFOX6)
Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746 and oxaliplatin	Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days
Safety Lead-in: Incidence of adverse events	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship as assessed by CTCAE 4.03
Safety Lead-in: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months
Safety Lead-in: Overall response rate by investigator	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
Safety Lead-in: Duration of response by Investigator	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
Safety Lead-in:Progression free survival by Investigator	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
Safety Lead-in: Time to response by Investigator	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months	Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
Safety Lead-in: Overall survival	After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 36 months	Overall survival defined as the time from the first dose to death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
Phase 3: Overall survival	Duration of Phase 3, approximately 50 months	Overall survival, defined as the time from the date of randomization to death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
Phase 3: Overall response rate by Investigator and by blinded independent review	Duration of Phase 3, approximately 36 months	Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
Phase 3: Duration of response by Investigator and blinded independent review	Duration of Phase 3, approximately 36 months	Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encoraf...
Phase 3: Time to response by blinded independent review and by Investigator	Duration of Phase 3, approximately 36 months	Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
Phase 3: Progression free survival by Investigator and by blinded independent review	Duration of Phase 3, approximately 36 months	Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause:: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm...
Phase 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)	Duration of Phase 3, approximately 36 months	EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point...
Phase 3: Change from Baseline in the Patient Global Impression of Severity (PGIS)	Duration of Phase 3, approximately 36 months	The PGIS is a single-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time.
Phase 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires	Duration of Phase 3, approximately 36 months	The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in symptoms or quality of life since starting treatment.
Phase 3: Confirm the MSI-status in tumor tissue	Once, pre-treatment	Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue
Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746 and oxaliplatin	Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days
Cohort 3: Progression free survival by Investigator and by blinded independent review	Duration of Cohort 3, approximately 21 months	Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause.
Cohort 3: Time to response by Investigator and by blinded independent review	Duration of Cohort 3, approximately 21 months	Time to response, defined as the time from the date of randomization to first radiographic evidence of response per RECIST v1.1
Cohort 3: To determine the correlation between ctDNA levels, BRAF V600 alterations, and clinical outcome	Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 15, Cycle 7 Day 1 and End of Treatment (Duration of Cohort 3, approximately 21 months). Each cycle is 28 days.	ctDNA levels and BRAF V600 VAF from ctDNA analysis of plasma samples collected at baseline and on treatment
Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746, irinotecan and SN-38	Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days
Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38	Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days.
Cohort 3: Overall response rate by investigator	Duration of Cohort 3, approximately 21 months	Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v 1.1
Cohort 3: Incidence of adverse events	Duration of Cohort 3, approximately 21 months	An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)
Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38	Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days
Cohort 3: Duration of response by Investigator and by blinded independent review	Duration of Cohort 3, approximately 21 months	Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause
Cohort 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms	Duration of Cohort 3, approximately 21 months	Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)
Phase 3: Trough concentrations of encorafenib and its metabolite LHY746	Predose on Cycle 1 through Cycle 6. Each cycle is 28 days	Trough plasma concentrations in all patients in Arm A and Arm B
Cohort 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)	Duration of Cohort 3, approximately 21 months	EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point...
Cohort 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire	Duration of Cohort 3, approximately 21 months	The EQ-5D-5L is a standardized measure of health utility that provides a single index value for the participant's health status. It is frequently used for economic evaluations of health care and has been shown to be a valid and reliable instrument, and comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitivel...
Cohort 3: Change from Baseline in the Patient Global Impression of Severity (PGIS)	Duration of Cohort 3, approximately 21 months	The PGIS is a single-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time.
Cohort 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires	Duration of Cohort 3, approximately 21 months	The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in symptoms or quality of life since starting treatment.
Cohort 3: Confirm the MSI-status in tumor tissue	Once, pre-treatment	Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue
Cohort 3: Trough concentrations of encorafenib and its metabolite LHY746	Predose on Cycle 1 through Cycle 6. Each cycle is 28 days	Trough plasma concentrations in all patients in Arm D

Trial Locations

Locations (381)

LAC & USC Medical Center; 🇺🇸 Los Angeles, California, United States

Cedars- Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Investigational Drug Service, The Ohio State University Wexner Medical Center; 🇺🇸 Columbus, Ohio, United States

The Ohio State University James Cancer Hospital and Solove Research Institute; 🇺🇸 Columbus, Ohio, United States

AHN Cancer Institute Pharmacy; 🇺🇸 Pittsburgh, Pennsylvania, United States

AHN Cancer Institute West Penn Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Seattle Cancer Care Alliance; 🇺🇸 Seattle, Washington, United States

Sylvester Comprehensive Cancer Center; 🇺🇸 Miami, Florida, United States

Baptist Hospital of Miami; 🇺🇸 Miami, Florida, United States

Haaglanden Medisch Centrum; 🇳🇱 Leidschendam, Zuid-holland, Netherlands

Rajiv Gandhi Cancer Institute And Research Centre; 🇮🇳 New Delhi, Delhi, India

R K Birla Cancer Center, SMS Hospital; 🇮🇳 Jaipur, Rajasthan, India

Hospital Bruno Born; 🇧🇷 Lajeado, RIO Grande DO SUL, Brazil

The First Affiliated Hospital of Anhui Medical University; 🇨🇳 Hefei, Anhui, China

Beijing Cancer hospital; 🇨🇳 Beijing, Beijing, China

Beijing Hospital; 🇨🇳 Beijing, Beijing, China

Chongqing University Cancer Hospital; 🇨🇳 Chongqing, Chongqing, China

Fujian Medical University Union Hospital-1 Bingfanglou; 🇨🇳 Fuzhou, Fujian, China

The Sixth Affiliated Hospital of Sun Yat-sen University; 🇨🇳 Guangzhou, Guangdong, China

Affiliated Tumor Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China

The Third Xiangya Hospital of Central South University; 🇨🇳 Changsha, Hunan, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology; 🇨🇳 Wuhan, Hubei, China

Shandong province cancer hospital; 🇨🇳 Jinan, Shandong, China

The Affiliated Hospital of Qingdao University; 🇨🇳 Qingdao, Shandong, China

Shanghai Jiaotong University School of Medicine Ruijin Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai General Hospital; 🇨🇳 Shanghai, Shanghai, China

The second Affiliated Hospital of College of Medicine, Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China

Peking University First Hospital; 🇨🇳 Beijing, China

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, China

Tianjin Union Medical Center; 🇨🇳 Tianjin, China

Vanderbilt Health Clinic at Walgreens Belle Meade; 🇺🇸 Nashville, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Donelson; 🇺🇸 Nashville, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Nippers Corner; 🇺🇸 Nashville, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Hart Lane; 🇺🇸 Nashville, Tennessee, United States

Henry-Joyce Cancer Center; 🇺🇸 Nashville, Tennessee, United States

Vanderbilt Oncology IDS Pharmacy; 🇺🇸 Nashville, Tennessee, United States

Satakunnan Keskussairaala; 🇫🇮 Pori, Finland

Fundação Faculdade Regional de Medicina de São José do Rio Preto; 🇧🇷 São José do Rio Preto, SÃO Paulo, Brazil

Centro Medico San Roque; 🇦🇷 Tucuman, Tucumán, Argentina

Medical Center Nadezhda Clinical EOOD; 🇧🇬 Sofia, Bulgaria

Reichow - Centro de Ensino e Pesquisa; 🇧🇷 Blumenau, Santa Catarina, Brazil

Medical School Famerp-HB-FUNFARME_Do not use - Duplicate facility; 🇧🇷 Sao jose do Rio Preto, SÃO Paulo, Brazil

MHAT Uni Hospital OOD; 🇧🇬 Panagyurishte, Pazardzhik, Bulgaria

Tampereen yliopistollinen sairaala; 🇫🇮 Tampere, Finland

Haukeland University Hospital; 🇳🇴 Bergen, Hordaland, Norway

MHAT Central Onco Hospital OOD; 🇧🇬 Plovdiv, Bulgaria

IRCCS Casa Sollievo della Sofferenza; 🇮🇹 San Giovanni Rotondo, Foggia, Italy

Kaohsiung Medical University Chung-Ho Memorial Hospital; 🇨🇳 Kaohsiung, Taiwan

Fundação Pio XII - Hospital de Câncer de Barretos; 🇧🇷 Barretos, SÃO Paulo, Brazil

Docrates Syöpäsairaala; 🇫🇮 Helsinki, Nyland, Finland

Accelerium, S. de R.L. de C.V.; 🇲🇽 Monterrey, Nuevo LEON, Mexico

Centro de Investigacion Clinica de Oaxaca; 🇲🇽 Oaxaca, Mexico

COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii; 🇵🇱 Gdansk, Poland

Hospital General Universitario de Elche; 🇪🇸 Elche, Alicante, Spain

China Medical University Hospital; 🇨🇳 Taichung, Taiwan

Bhakti Vedanta Hospital and Research Institute; 🇮🇳 Thane, Maharashtra, India

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

National Cancer Center; 🇰🇷 Goyang-si, Gyeonggi-do, Korea, Republic of

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan

Turku University Hospital; 🇫🇮 Turku, Finland

Przychodnia Lekarska KOMED; 🇵🇱 Konin, Poland

Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza; 🇵🇱 Brzozow, Poland

Deenanath Mangeshkar Hospital & Research Centre; 🇮🇳 Pune, Maharashtra, India

Cape Town Oncology Trials; 🇿🇦 Cape Town, Western CAPE, South Africa

Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica; 🇸🇰 Banska Bystrica, Slovakia

Mayo Clinic - Phoenix Oncology Pharmacy; 🇺🇸 Phoenix, Arizona, United States

Vejle Sygehus; 🇩🇰 Vejle, Syddanmark, Denmark

Providence Cancer Institute Franz Clinic; 🇺🇸 Portland, Oregon, United States

Providence Portland Medical Center; 🇺🇸 Portland, Oregon, United States

Providence Oncology and Hematology Care Clinic - Westside; 🇺🇸 Portland, Oregon, United States

Providence St. Vincent Medical Center; 🇺🇸 Portland, Oregon, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

Mayo Clinic Rochester; 🇺🇸 Rochester, Minnesota, United States

Oncology Hematology West, PC dba Nebraska Cancer Specialists - IP Storage; 🇺🇸 Omaha, Nebraska, United States

Froedtert Hospital and the Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

The West Clinic. PLLC. dba West Cancer Center; 🇺🇸 Germantown, Tennessee, United States

The West Clinic PLLC dba West Cancer Center; 🇺🇸 Memphis, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Hendersonville; 🇺🇸 Hendersonville, Tennessee, United States

Vanderbilt Health Clinic at Walgreens La Vergne; 🇺🇸 La Vergne, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Murfreesboro; 🇺🇸 Murfreesboro, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Bellevue; 🇺🇸 Nashville, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Smyrna; 🇺🇸 Smyrna, Tennessee, United States

Summit Cancer Care; 🇺🇸 Savannah, Georgia, United States

UChicago Medicine - River East; 🇺🇸 Chicago, Illinois, United States

The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy; 🇺🇸 Chicago, Illinois, United States

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

UChicago Medicine at Ingalls - Flossmoor; 🇺🇸 Flossmoor, Illinois, United States

UChicago Medicine Ingalls Memorial; 🇺🇸 Harvey, Illinois, United States

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital; 🇺🇸 New Lenox, Illinois, United States

UChicago Medicine at Ingalls - Tinley Park; 🇺🇸 Tinley Park, Illinois, United States

Mayo Clinic in Rochester, Minnesota; 🇺🇸 Rochester, Minnesota, United States

Siteman Cancer Center - West County; 🇺🇸 Creve Coeur, Missouri, United States

Siteman Cancer Center - North County; 🇺🇸 Florissant, Missouri, United States

Siteman Cancer Center - South County; 🇺🇸 Saint Louis, Missouri, United States

Barnes- Jewish Hospital; 🇺🇸 Saint Louis, Missouri, United States

St. Vincent Frontier Cancer Center; 🇺🇸 Billings, Montana, United States

Oncology Hematology West PC dba Nebraska Cancer Specialists; 🇺🇸 Papillion, Nebraska, United States

Siteman Cancer Center - St Peters; 🇺🇸 Saint Peters, Missouri, United States

St Vincent Healthcare; 🇺🇸 Billings, Montana, United States

Memorial Sloan Kettering Cancer Center - Basking Ridge; 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Cancer Center- Monmouth; 🇺🇸 Middletown, New Jersey, United States

Summit Medical Group; 🇺🇸 Florham Park, New Jersey, United States

Memorial Sloan Kettering Cancer Center- Bergen; 🇺🇸 Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center Commack; 🇺🇸 Commack, New York, United States

North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists; 🇺🇸 Riverhead, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Levine Cancer Institute; 🇺🇸 Charlotte, North Carolina, United States

Atrium Health Mercy; 🇺🇸 Charlotte, North Carolina, United States

Atrium Health Pineville; 🇺🇸 Charlotte, North Carolina, United States

Atrium Health University City; 🇺🇸 Charlotte, North Carolina, United States

Levine Cancer Institute University City; 🇺🇸 Charlotte, North Carolina, United States

Cleveland Clinic Taussig Cancer Center Investigational Pharmacy; 🇺🇸 Cleveland, Ohio, United States

Stefanie Spielman Comprehensive Breast Cancer; 🇺🇸 Columbus, Ohio, United States

Atrium Health Union; 🇺🇸 Monroe, North Carolina, United States

The James Outpatient Care West Campus; 🇺🇸 Columbus, Ohio, United States

University of Oklahoma Health Sciences Center, OU Health Stephenson Cancer Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Martha Morehouse Medical Plaza; 🇺🇸 Columbus, Ohio, United States

Providence Onc and Heme Care Clinic - Westside; 🇺🇸 Portland, Oregon, United States

Providence St Vincent Medical Center; 🇺🇸 Portland, Oregon, United States

AHN Cancer Institute at Jefferson Hospital; 🇺🇸 Jefferson Hills, Pennsylvania, United States

AHN Cancer Institute - Allegheny General Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

AHN Cancer Institute Forbes Hospital; 🇺🇸 Monroeville, Pennsylvania, United States

UPMC Hillman Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

UPMC Hillman Cancer Center Investigational Drug Service; 🇺🇸 Pittsburgh, Pennsylvania, United States

Wexford Health and Wellness Pavilion; 🇺🇸 Wexford, Pennsylvania, United States

Vanderbilt Health Clinic at Walgreens Clarksville; 🇺🇸 Clarksville, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Cool Springs; 🇺🇸 Franklin, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Hermitage; 🇺🇸 Hermitage, Tennessee, United States

Vanderbilt Health Clinic at Walgreens Lebanon; 🇺🇸 Lebanon, Tennessee, United States

Vanderbilt-Ingram Cancer Center; 🇺🇸 Nashville, Tennessee, United States

Clinica Universitaria Reina Fabiola; 🇦🇷 Cordoba, Argentina

Royal Brisbane & Women's Hospital; 🇦🇺 Herston, Queensland, Australia

Clínica de Neoplasias Litoral; 🇧🇷 Itajaí, Santa Catarina, Brazil

MHAT "Dr. Tota Venkova" AD; 🇧🇬 Gabrovo, Bulgaria

Fakultni nemocnice Olomouc; 🇨🇿 Olomouc, Czechia

Memorial Sloan Kettering Cancer Center - Westchester; 🇺🇸 Harrison, New York, United States

Memorial Sloan Kettering Cancer Center - Main Campus; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center- Nassau; 🇺🇸 Uniondale, New York, United States

Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus; 🇩🇪 Dresden, Germany

Helios Klinikum Berlin-Buch; 🇩🇪 Berlin, Germany

Facharztzentrum Eppendorf; 🇩🇪 Hamburg, Germany

Radiologie im Israelitischen Krankenhaus; 🇩🇪 Hamburg, Germany

Universitätsklinikum Carl Gustav Carus Dresden; 🇩🇪 Dresden, Germany

ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld; 🇩🇪 Hamburg, Germany

Klinikum Oldenburg AöR; 🇩🇪 Oldenburg, Germany

Tata Memorial Hospital; 🇮🇳 Mumbai, Maharashtra, India

Sahyadri Speciality Hospital; 🇮🇳 Pune, Maharashtra, India

Sawai Man Singh Medical College Hospital (SMS Hospital); 🇮🇳 Jaipur, Rajasthan, India

Fondazione del Piemonte per l'Oncologia - Istituto di Candiolo IRCCS; 🇮🇹 Candiolo, Torino, Italy

ASST Grande Ospedale Metropolitano Niguarda; 🇮🇹 Milan, Milano, Italy

Azienda Ospedaliero Universitaria San Luigi Gonzaga; 🇮🇹 Orbassano, Torino, Italy

Azienda Ospedaliera Universitaria dell'Università "Luigi Vanvitelli" di Napoli; 🇮🇹 Napoli, Italy

Fondazione Poliambulanza Istituto Ospedaliero; 🇮🇹 Brescia, Italy

Istituto Europeo di Oncologia IRCCS; 🇮🇹 Milano, Italy

IRCCS Istituto Oncologico Veneto (IOV); 🇮🇹 Padova, Italy

National Hospital Organization Shikoku Cancer Center; 🇯🇵 Matsuyama, Ehime, Japan

Azienda USL - IRCCS di Reggio Emilia - Arcispedale Santa Maria Nuova; 🇮🇹 Reggio Emilia, Italy

Kanazawa University Hospital; 🇯🇵 Kanazawa, Ishikawa, Japan

St. Marianna University Hospital; 🇯🇵 Kawasaki, Kanagawa, Japan

Kanagawa cancer center; 🇯🇵 Yokohama, Kanagawa, Japan

Kindai University Hospital; 🇯🇵 Osakasayama, Osaka, Japan

Osaka Prefectural Hospital Organization Osaka International Cancer Institute; 🇯🇵 Osaka-shi, Osaka, Japan

Osaka University Hospital; 🇯🇵 Suita, Osaka, Japan

Japanese Foundation for Cancer Research; 🇯🇵 Koto-ku, Tokyo, Japan

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research; 🇯🇵 Osaka, Japan

National Hospital Organization Kyushu Cancer Center; 🇯🇵 Fukuoka, Japan

Keio university hospital; 🇯🇵 Tokyo, Japan

Dong-A University Hospital; 🇰🇷 Busan, Korea, Republic of

Chonnam National University Hwasun Hospital Pharmacy; 🇰🇷 Jeonnam, Korea, Republic of

Chonnam National University Hwasun Hospital; 🇰🇷 Jeonnam, Korea, Republic of

Korea University Anam Hospital; 🇰🇷 Seoul, Korea, Republic of

Gachon University Gil Medical Center; 🇰🇷 Incheon, Korea, Republic of

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Maastricht UMC+; 🇳🇱 Maastricht, Limburg, Netherlands

Tauranga Hospital; 🇳🇿 Tauranga, BAY OF Plenty, New Zealand

Maastricht University Medical Center; 🇳🇱 Maastricht, Netherlands

Auckland City Hospital; 🇳🇿 Auckland, New Zealand

Universitair Medisch Centrum Utrecht; 🇳🇱 Utrecht, Netherlands

St. Olavs hospital; 🇳🇴 Trondheim, Sør-trøndelag, Norway

Auckland District Health Board Charitable Trust; 🇳🇿 Auckland, New Zealand

Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii; 🇵🇱 Bytom, Poland

Sørlandet Sykehus Kristiansand; 🇳🇴 Kristiansand, Vest-agder, Norway

Oslo Universitetssykehus Ullevål; 🇳🇴 Oslo, Norway

Kaluga Regional Clinical Oncology Center; 🇷🇺 Kaluga, Russian Federation

FSAEI HE I.M Sechenov First MSMU MoH Russia (Sechenovskiy University),; 🇷🇺 Moscow, Russian Federation

GBUZ; 🇷🇺 Chelyabinsk, Russian Federation

LLC "EuroCityClinic"; 🇷🇺 Saint Petersburg, Russian Federation

BHI of Omsk Region "Clinical Oncology Dispensary"; 🇷🇺 Omsk, Russian Federation

Onkologicky ustav sv. Alzbety s.r.o.; 🇸🇰 Bratislava, Slovakia

Narodny Onkologicky Ustav; 🇸🇰 Bratislava, Slovakia

Cancercare Rondebosch Oncology; 🇿🇦 Rondebosch, Cape Town, South Africa

POKO Poprad s.r.o.; 🇸🇰 Poprad, Slovakia

Cancercare Langenhoven Drive Oncology Centre; 🇿🇦 Port Elizabeth, Eastern CAPE, South Africa

Wits Clinical Research; 🇿🇦 Parktown, Johannesburg, Gauteng, South Africa

Complejo Hospitalario Universitario Santiago de Compostela; 🇪🇸 Santiago de Compostela, A Coruña, Spain

Wits Health Consortium (Pty) Ltd; 🇿🇦 Johannesburg, South Africa

Hospital Universitario Vall d'Hebron; 🇪🇸 Barcelona, Spain

Akademiska sjukhuset; 🇸🇪 Uppsala, Uppsala LÄN [se-03], Sweden

Norrlands universitetssjukhus; 🇸🇪 Umeå, Västerbottens LÄN [se-24], Sweden

Taipei Medical University Hospital; 🇨🇳 Taipei, Taiwan

Chang Gung Medical Foundation-Linkou Branch; 🇨🇳 Taoyuan, Taiwan

Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council; 🇺🇦 Dnipro, Ukraine

PRECARPATHIAN NUCLEAR MEDICINE CENTER, Limited Liability Company; 🇺🇦 Ivano-Frankivsk, Ukraine

Vanderbilt Health Clinic at Walgreens Gallatin; 🇺🇸 Gallatin, Tennessee, United States

Carolinas Medical Center; 🇺🇸 Charlotte, North Carolina, United States

Carolinas Medical Center Investigational Drug Services; 🇺🇸 Charlotte, North Carolina, United States

Levine Cancer Institute - Southpark; 🇺🇸 Charlotte, North Carolina, United States

Atrium Health Cabarrus; 🇺🇸 Concord, North Carolina, United States

Mayo Clinic Hospital; 🇺🇸 Phoenix, Arizona, United States

Mayo Clinic in Arizona - Scottsdale; 🇺🇸 Scottsdale, Arizona, United States

Keck Hospital of USC; 🇺🇸 Los Angeles, California, United States

Tower Hematology Oncology Medical Group (THO); 🇺🇸 Beverly Hills, California, United States

USC / Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

USC/Norris Comprehensive Cancer Center / Investigational Drug Services; 🇺🇸 Los Angeles, California, United States

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute; 🇺🇸 Los Angeles, California, United States

Cedars-Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Keck Hospital of USC Pasadena; 🇺🇸 Pasadena, California, United States

Torrance Memorial Medical Center (TMMC); 🇺🇸 Torrance, California, United States

Mount Sinai Comprehensive Cancer Center, Aventura; 🇺🇸 Aventura, Florida, United States

Georgetown University Medical Center; 🇺🇸 Washington, District of Columbia, United States

Medstar Georgetown University Hospital; 🇺🇸 Washington, District of Columbia, United States

Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center; 🇺🇸 Coral Gables, Florida, United States

Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center; 🇺🇸 Fort Lauderdale, Florida, United States

Mayo Clinic Florida; 🇺🇸 Jacksonville, Florida, United States

Mount Sinai Comprehensive Cancer Center; 🇺🇸 Miami Beach, Florida, United States

Miami Cancer Institute; 🇺🇸 Miami, Florida, United States

BRCR Global; 🇺🇸 Plantation, Florida, United States

BRCR Medical Center Inc.; 🇺🇸 Plantation, Florida, United States

Lewis Cancer & Research Pavilion at St Joseph's/Candler Health System; 🇺🇸 Savannah, Georgia, United States

St. Joseph's/Candler Health System, Inc.; 🇺🇸 Savannah, Georgia, United States

Summit Cancer Care, P.C.; 🇺🇸 Savannah, Georgia, United States

University of Washington Medical Center; 🇺🇸 Seattle, Washington, United States

University of Wisconsin Clinical Science Center; 🇺🇸 Madison, Wisconsin, United States

Instituto Médico Especializado Alexander Fleming; 🇦🇷 Ciudad Autónoma de Buenos Aires, Argentina

Liverpool Hospital; 🇦🇺 Liverpool, New South Wales, Australia

Slade Pharmacy; 🇦🇺 Mount Kuring-Gai, New South Wales, Australia

GenesisCare - North Shore; 🇦🇺 St Leonards, New South Wales, Australia

GenesisCare North Shore; 🇦🇺 St Leonards, New South Wales, Australia

The Queen Elizabeth Hospital; 🇦🇺 Adelaide, South Australia, Australia

Princess Alexandra Hospital; 🇦🇺 Woolloongabba, Queensland, Australia

Peter MacCallum Cancer Centre; 🇦🇺 Melbourne, Victoria, Australia

Monash Health; 🇦🇺 Clayton, Victoria, Australia

Université Libre de Bruxelles - Hôpital Erasme; 🇧🇪 Brussels, Bruxelles-capitale, Région DE, Belgium

Austin Health; 🇦🇺 Heidelberg, Victoria, Australia

Cliniques universitaires Saint-Luc; 🇧🇪 Brussels, Bruxelles-capitale, Région DE, Belgium

CHR Verviers East Belgium; 🇧🇪 Verviers, Liège, Belgium

Grand Hôpital de Charleroi; 🇧🇪 Charleroi, Hainaut, Belgium

Hospital de Clinicas de Porto Alegre; 🇧🇷 Porto Alegre, RIO Grande DO SUL, Brazil

Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman; 🇧🇪 Liège, Belgium

AZ Groeninge Campus Kennedylaan; 🇧🇪 Kortrijk, West-vlaanderen, Belgium

ZNA Middelheim; 🇧🇪 Antwerpen, Belgium

UZ Leuven; 🇧🇪 Leuven, Belgium

Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA; 🇧🇷 Rio de Janeiro, RJ, Brazil

CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC; 🇧🇷 Santo André, SP, Brazil

INCA; 🇧🇷 Rio de Janeiro, RJ, Brazil

Hospital do Cancer de Barretos - Fundacao Pio XII; 🇧🇷 Barretos, SP, Brazil

FUNDAÇÃO DO ABC - Faculdade de Medicina do ABC - Centro de Estudos e Pesquisas de Hematologia e Onco; 🇧🇷 Santo Andre, SP, Brazil

Fundacao do ABC-Faculdade de Medicina do ABC; 🇧🇷 Santo Andre, SP, Brazil

Complex Oncology Center - Plovdiv EOOD; 🇧🇬 Plovdiv, Bulgaria

Acibadem City Clinic MHAT Tokuda; 🇧🇬 Sofia, Bulgaria

Tom Baker Cancer Centre; 🇨🇦 Calgary, Alberta, Canada

Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

University Multiprofile Hospital for Active Treatment Sofiamed; 🇧🇬 Sofia, Bulgaria

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada

London Regional Cancer Program, London Health Sciences Centre; 🇨🇦 London, Ontario, Canada

Kingston Health Sciences Centre-Kingston General Hospital Site; 🇨🇦 Kingston, Ontario, Canada

Centre Intégré de Santé et de Services Sociaux (CISSS) de Laval / Hôpital de la Cité-de-la-Sant; 🇨🇦 Laval, Quebec, Canada

Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

Anhui Provincial Cancer Hospital; 🇨🇳 Hefei, Anhui, China

Cancer Hospital Chinese Academy of Medical Science; 🇨🇳 Beijing, Beijing, China

Guangdong Provincial People's Hospital; 🇨🇳 Guangzhou, Guangdong, China

Henan provincial people's hospital; 🇨🇳 Zhengzhou, Henan, China

The Second Xiangya Hospital of Central South University; 🇨🇳 Changsha, Hunan, China

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School; 🇨🇳 Nanjing, Jiangsu, China

Jinan Central Hospital; 🇨🇳 Jinan, Shandong, China

Aalborg Universitetshospital; 🇩🇰 Aalborg, Denmark

Lewis Cancer & Research Pavilion Pharmacy; 🇺🇸 Savannah, Georgia, United States

Sichuan Province Cancer Hospital; 🇨🇳 Chengdu, Sichuan, China

Yunnan Cancer Hospital(The Third Affiliated Hospital of Kunming Medical University); 🇨🇳 Kunming, Yunnan, China

Fakultni nemocnice Hradec Kralove; 🇨🇿 Hradec Kralove, Hradec Králové, Czechia

Fakultni nemocnice v Motole; 🇨🇿 Praha 5, Czechia

Aalborg Universitetshospital, Syd; 🇩🇰 Aalborg, Nordjylland, Denmark

Fakultni nemocnice Bulovka; 🇨🇿 Praha 8, Czechia

Vejle Hospital-Sygehus Lillebaelt; 🇩🇰 Vejle, Syddanmark, Denmark

Rigshospitalet; 🇩🇰 Copenhagen, Denmark

Herlev and Gentofte Hospital; 🇩🇰 Herlev, Denmark

Odense University Hospital; 🇩🇰 Odense C, Denmark

Chris O'Brien Lifehouse; 🇦🇺 Camperdown, New South Wales, Australia

Helsinki University Central Hospital; 🇫🇮 Helsinki, Finland

Oulu University Hospital; 🇫🇮 Oulu, Finland

Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie; 🇩🇪 Muenchen, Bayern, Germany

Medizinische Hochschule Hannover; 🇩🇪 Hannover, Niedersachsen, Germany

Waage Apotheke; 🇩🇪 Berlin, Germany

Universitätsklinikum Leipzig; 🇩🇪 Leipzig, Sachsen, Germany

Radiologie Berlin; 🇩🇪 Berlin - Charlottenburg, Germany

HELIOS Klinikum Berlin Buch GmbH; 🇩🇪 Berlin, Germany

Institut für Klinisch Onkologische Forschung; 🇩🇪 Frankfurt, Hessen, Germany

Azienda Ospedaliera Universitaria di Cagliari - Presidio Policlinico Universitario "D.Casula"; 🇮🇹 Monserrato (CA), Cagliari, Italy

Alfred Health; 🇦🇺 Melbourne, Victoria, Australia

National Cancer Center Hospital East; 🇯🇵 Kashiwa, Chiba, Japan

Hokkaido University Hospital; 🇯🇵 Sapporo, Hokkaido, Japan

Chiba cancer center; 🇯🇵 Chiba-shi, Chiba, Japan

Aichi Cancer Center Hospital; 🇯🇵 Nagoya, Nagoya, Aichi, Japan

Saitama Medical University International Medical Center; 🇯🇵 Hidaka-city, Saitama, Japan

Saitama Prefectural Cancer Center; 🇯🇵 Ina-machi, Saitama, Japan

Shizuoka Cancer Center; 🇯🇵 Nagaizumi, Shizuoka, Japan

National Cancer Center Hospital; 🇯🇵 Chuo-ku, Tokyo, Japan

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Kyungpook National University Chilgok Hospital; 🇰🇷 Daegu, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL); 🇳🇱 Amsterdam, Noord-holland, Netherlands

Catharina Ziekenhuis; 🇳🇱 Eindhoven, Noord-brabant, Netherlands

Amsterdam UMC, location VUMc; 🇳🇱 Amsterdam, Netherlands

Stavanger Universitetssykehus; 🇳🇴 Stavanger, Rogaland, Norway

Oslo universitetssykehus, Radiumhospitalet; 🇳🇴 Oslo, Norway

COPERNICUS PL sp. z. o. o. Wojewodzkie Centrum Onkologii w Gdansku Ambulatoryjna; 🇵🇱 Gdansk, Poland

Private Medical Institution "Euromedservice"; 🇷🇺 Pushkin, Sankt-peterburg, Russian Federation

FSBI "Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov; 🇷🇺 St. Petersburg, Russian Federation

SHI YR Regional Clinical Oncology Hospital; 🇷🇺 Yaroslav, Russian Federation

LLC "Severo-Zapadny Medical Center"; 🇷🇺 Saint-Petersburg, Russian Federation

Shengjing Hospital Of China Medical University; 🇨🇳 Shenyang, Liaoning, China

Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of St. Petersburg; 🇷🇺 Saint-Petersburg, Russian Federation

Vychodoslovensky onkologicky ustav, a.s.; 🇸🇰 Kosice, Slovakia

Mary Potter Oncology Centre; 🇿🇦 Pretoria, South Africa

ICO L'Hospitalet (Hospital Duran i Reynals); 🇪🇸 Hospitalet de Llobregat, Barcelona, Spain

Hospital Clinic Barcelona; 🇪🇸 Barcelona, Spain

Hospital Universitario 12 de octubre; 🇪🇸 Madrid, Spain

Hospital Universitario Virgen Del Rocio; 🇪🇸 Sevilla, Spain

Hospital General Universitario Gregorio Marañon; 🇪🇸 Madrid, Spain

Hospital Universitario Ramon Y Cajal; 🇪🇸 Madrid, Spain

Hospital Clinico Universitario de Valencia; 🇪🇸 Valencia, Spain

Hospital General Universitario de Valencia; 🇪🇸 Valencia, Spain

Hospital Universitario Miguel Servet; 🇪🇸 Zaragoza, Spain

Karolinska Universitetssjukhuset Solna; 🇸🇪 Solna, Stockholms LÄN [se-01], Sweden

Sahlgrenska Universitetssjukhuset; 🇸🇪 Göteborg, Västra Götalands LÄN [se14], Sweden

National Cheng-Kung University Hospital; 🇨🇳 Tainan, Taiwan

Chi Mei Hospital, Liouying; 🇨🇳 Tainan, Taiwan

Medical and diagnostic center of MediX-Ray International Group LLC Israeli Oncology Hospital "LISOD"; 🇺🇦 Pliuty Village, KYIV Region, Obuhovskiy District, Ukraine

MNPE "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Regional Council"; 🇺🇦 Ivano-Frankivsk, Ukraine

Ivano-Frankivsk National Medical University; 🇺🇦 Ivano-Frankivsk, Ukraine

Communal Non-Profit Enterprise "Regional Center of Oncology"; 🇺🇦 Kharkiv, Ukraine

Municipal non-profit enterprise "City clinical hospital #2 named after O.O.Shalimov"; 🇺🇦 Kharkiv, Ukraine

Communal enterprise "Kryvyi Rih Oncology Dispensary" of Dnipropetrovsk Regional Council; 🇺🇦 Kryvyi Rih, Ukraine

SI "Insitute of Neurosurgery n.a.acad. A.P.; 🇺🇦 Kyiv, Ukraine

Instituto do Cancer do Estado de Sao Paulo, ICESP; 🇧🇷 Sao Paulo, SP, Brazil

Municipal non-profit enterprise of Kyiv regional council "Kyiv regional clinical hospital"; 🇺🇦 Kyiv, Ukraine

Municipal non-profit enterprise "Zaporizhzhia Regional Antitumor Center" Zaporizhzhia Regional; 🇺🇦 Zaporizhzhia, Ukraine

Freeman Hospital; 🇬🇧 Newcastle upon Tyne, HIGH Heaton, United Kingdom

Royal Marsden NHS Foundation Trust; 🇬🇧 London, United Kingdom

Heartlands Hospital; 🇬🇧 Birmingham, United Kingdom

Churchill Hospital - Oncology; 🇬🇧 Oxford, United Kingdom

Hammersmith Hospital, Imperial College Healthcare NHS Trust; 🇬🇧 London, United Kingdom

Hammersmith Hospital; 🇬🇧 London, United Kingdom

Levine Cancer Institute - Concord; 🇺🇸 Concord, North Carolina, United States

LLC "Medicina Severnoy Stolitsy"; 🇷🇺 Saint-Petersburg, Russian Federation

Fakultni Thomayerova nemocnice; 🇨🇿 Prague, Praha 4, Czechia

Charlotte Maxeke Johannesburg Academic Hospital; 🇿🇦 Johannesburg, Gauteng, South Africa

Onkologische Schwerpunktpraxis Kurfuerstendamm; 🇩🇪 Berlin, Germany

Hospital Privado Centro Médico de Córdoba; 🇦🇷 Córdoba, Argentina

Kyungpook National University Hospital; 🇰🇷 Daegu, Taegu-kwangyǒkshi, Korea, Republic of

Mount Sinai Medical Center; 🇺🇸 Miami Beach, Florida, United States

The University of Chicago Medicine Center for Advanced Care Orland Park; 🇺🇸 Orland Park, Illinois, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Fakultní nemocnice Brno Bohunice; 🇨🇿 Brno, Brno-město, Czechia

Osaka Medical and Pharmaceutical University Hospital; 🇯🇵 Takatsuki, Osaka, Japan

University of Michigan Hospitals; 🇺🇸 Ann Arbor, Michigan, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Orlando Health, Inc; 🇺🇸 Orlando, Florida, United States

Orlando Health Cancer Institute; 🇺🇸 Orlando, Florida, United States

Orlando Health, Inc.; 🇺🇸 Orlando, Florida, United States

Ochsner Clinic Foundation Research Pharmacy; 🇺🇸 New Orleans, Louisiana, United States

Ochsner Clinic Foundation; 🇺🇸 New Orleans, Louisiana, United States

VCU Health - Adult Outpatient Pavilion (AOP) Investigational Drug Services; 🇺🇸 Richmond, Virginia, United States

VCU Health System, Investigational Drug Service Pharmacy; 🇺🇸 Richmond, Virginia, United States

Virginia Commonwealth University Massey Cancer Center; 🇺🇸 Richmond, Virginia, United States

Virginia Commonwealth University; 🇺🇸 Richmond, Virginia, United States

The University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Arthur J.E. Child Comprehensive Cancer Centre; 🇨🇦 Calgary, Alberta, Canada